Treatment trends in patients with de novo metastatic prostate cancer in the era of upfront combination therapy
Upfront combination therapy use has 72% and 54% prevalence among patients with high and low tumor burden diseases, respectively, in this current practice. Older age, poor performance status, and facility bias were negatively associated with the use of upfront combination therapy.
Authors
- Osamu Soma
- Shingo Hatakeyama (ORCID: https://orcid.org/0000-0002-0026-4079)
- Ryuji Tabata (ORCID: https://orcid.org/0000-0003-1286-3359)
- Teppei Okamoto (ORCID: https://orcid.org/0000-0002-3750-3811)
- Daisuke Noro (ORCID: https://orcid.org/0000-0002-7104-0945)
- Takuya Oishi (ORCID: https://orcid.org/0000-0001-7411-8237)
- Satoshi Sato (ORCID: https://orcid.org/0000-0003-0459-4128)
- Shingo Moriyama (ORCID: https://orcid.org/0000-0002-3932-4470)
- Hikari Miura
- Hirotaka Horiguchi
- Toshikazu Tanaka (ORCID: https://orcid.org/0000-0002-0711-7880)
- Chikara Οhyama (ORCID: https://orcid.org/0000-0003-1550-8379)
- Daiji Fujimori
- Yohei Kawashima
- Hayato Yamamoto
Institutions
- Hirosaki University (JP)
- Aomori Prefectural Central Hospital (JP)
- Odawara Municipal Hospital (JP)
- Hakodate Central General Hospital (JP)
Publication Details
- Journal
- International Journal of Urology
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1111/iju.15550
- Citations
- 4
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Japan Society for the Promotion of Science